High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem Therapy.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
20 12 2019
Historique:
received: 01 07 2019
accepted: 14 10 2019
pubmed: 23 10 2019
medline: 1 9 2020
entrez: 23 10 2019
Statut: epublish

Résumé

OXA-232 is an OXA-48-group class D β-lactamase that hydrolyzes expanded-spectrum cephalosporins and carbapenems at low levels. Clinical strains producing OXA-232 are sometimes susceptible to carbapenems, making it difficult to identify them in the clinical microbiology laboratory. We describe the development of carbapenem resistance in sequential clinical isolates of

Identifiants

pubmed: 31636064
pii: AAC.01335-19
doi: 10.1128/AAC.01335-19
pmc: PMC7187609
pii:
doi:

Substances chimiques

Bacterial Proteins 0
Carbapenems 0
OmpC protein 0
OmpF protein 0
Porins 0
beta-Lactamases EC 3.5.2.6
carbapenemase EC 3.5.2.6
Ertapenem G32F6EID2H

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NIAID NIH HHS
ID : K08 AI114883
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI104895
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI124302
Pays : United States
Organisme : NIAID NIH HHS
ID : R03 AI144636
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI135522
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM110444
Pays : United States

Informations de copyright

Copyright © 2019 American Society for Microbiology.

Références

Antimicrob Agents Chemother. 2011 May;55(5):2420-3
pubmed: 21343451
Antimicrob Agents Chemother. 2011 Mar;55(3):1274-8
pubmed: 21189345
Clin Microbiol Infect. 2016 Mar;22(3):252-7
pubmed: 26577139
Infection. 2016 Dec;44(6):713-717
pubmed: 27147419
Clin Microbiol Infect. 2013 Feb;19(2):E72-9
pubmed: 23231088
PLoS One. 2015 May 22;10(5):e0128036
pubmed: 26000737
Antimicrob Agents Chemother. 2011 Apr;55(4):1485-93
pubmed: 21282452
J Clin Microbiol. 2017 Aug;55(8):2321-2333
pubmed: 28381609
Antimicrob Agents Chemother. 2004 Jan;48(1):15-22
pubmed: 14693513
Emerg Infect Dis. 2018 Apr;24(4):700-709
pubmed: 29553324
Antimicrob Agents Chemother. 2014;58(3):1678-83
pubmed: 24379200
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Int J Infect Dis. 2016 Apr;45:65-71
pubmed: 26921549
Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):587-604
pubmed: 28990132
Folia Microbiol (Praha). 2017 May;62(3):221-227
pubmed: 28063019
Antimicrob Agents Chemother. 2004 Jan;48(1):305-12
pubmed: 14693555
J Med Microbiol. 2011 Apr;60(Pt 4):492-499
pubmed: 21212145
J Antimicrob Chemother. 2012 Jul;67(7):1597-606
pubmed: 22499996
Int J Antimicrob Agents. 2013 Apr;41(4):325-9
pubmed: 23305656
Int J Syst Evol Microbiol. 2001 May;51(Pt 3):925-932
pubmed: 11411716

Auteurs

Alina Iovleva (A)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Roberta T Mettus (RT)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Christi L McElheny (CL)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Marissa P Griffith (MP)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Mustapha M Mustapha (MM)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

A William Pasculle (AW)

Clinical Microbiology Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Ryan K Shields (RK)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Vaughn S Cooper (VS)

Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Microbiology and Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

Yohei Doi (Y)

Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA yod4@pitt.edu.
Center for Innovative Antimicrobial Therapy, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Department of Microbiology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
Department of Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH